TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FUROSCIX

FUROSEMIDE
Cardiovascular Approved 2022-10-07
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
4
Indications
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-10-07
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

SCPHARMACEUTICALS
Active Ingredient: FUROSEMIDE

FUROSCIX Approval History

Loading approval history...

What FUROSCIX Treats

4 indications

FUROSCIX is approved for 4 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Edema
  • Chronic Heart Failure
  • Chronic Kidney Disease
  • Nephrotic Syndrome
Source: FDA Label

Drugs Similar to FUROSCIX

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALDACTONE
SPIRONOLACTONE
2 shared
Pfizer
Shared indications:
EdemaNephrotic Syndrome
BUMETANIDE
BUMETANIDE
2 shared
MSN
Shared indications:
EdemaNephrotic Syndrome
BUMEX
BUMETANIDE
2 shared
VALIDUS PHARMS
Shared indications:
EdemaNephrotic Syndrome
DYRENIUM
TRIAMTERENE
2 shared
ADVANZ PHARMA
Shared indications:
EdemaNephrotic Syndrome
EDECRIN
ETHACRYNIC ACID
2 shared
BAUSCH
Shared indications:
EdemaNephrotic Syndrome
ENBUMYST
BUMETANIDE
2 shared
CORSTASIS THERAP
Shared indications:
EdemaNephrotic Syndrome
ETHACRYNATE SODIUM
ETHACRYNATE SODIUM
2 shared
PH HEALTH
Shared indications:
EdemaNephrotic Syndrome
HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE
2 shared
JUBILANT CADISTA
Shared indications:
EdemaNephrotic Syndrome
INZIRQO
HYDROCHLOROTHIAZIDE
2 shared
NOVITIUM PHARMA
Shared indications:
EdemaNephrotic Syndrome
METOLAZONE
METOLAZONE
2 shared
Novartis
Shared indications:
EdemaNephrotic Syndrome
THALITONE
CHLORTHALIDONE
2 shared
CASPER PHARMA LLC
Shared indications:
EdemaNephrotic Syndrome
ACETAZOLAMIDE
ACETAZOLAMIDE
1 shared
MANKIND PHARMA
Shared indications:
Edema
AURYXIA
FERRIC CITRATE
1 shared
KERYX BIOPHARMS
Shared indications:
Chronic Kidney Disease
CAROSPIR
SPIRONOLACTONE
1 shared
CMP DEV LLC
Shared indications:
Edema
DOXERCALCIFEROL
DOXERCALCIFEROL
1 shared
CAPLIN
Shared indications:
Chronic Kidney Disease
EPOGEN/PROCRIT
EPOETIN ALFA
1 shared
Amgen
Shared indications:
Chronic Kidney Disease
FARXIGA
DAPAGLIFLOZIN
1 shared
AstraZeneca
Shared indications:
Chronic Kidney Disease
FERAHEME
FERUMOXYTOL
1 shared
COVIS
Shared indications:
Chronic Kidney Disease
FERRLECIT
SODIUM FERRIC GLUCONATE COMPLEX
1 shared
Sanofi
Shared indications:
Chronic Kidney Disease
FERUMOXYTOL
FERUMOXYTOL
1 shared
Novartis
Shared indications:
Chronic Kidney Disease
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FUROSCIX FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

FUROSCIX is indicated for the treatment of edema in pediatric patients weighing 43 kg and above and in adult patients adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome. FUROSCIX is a loop diuretic indicated for the treatment of edema in pediatric patients weighing 43 kg and above and in adult patients with chronic heart failure or chronic kidney disease, including the nephrotic syndrome.

FUROSCIX Patents & Exclusivity

Latest Patent: Apr 2034

Patents (4 active)

US11433044 Expires Apr 3, 2034
US9884039 Expires Apr 3, 2034
US12370168 Expires Apr 3, 2034
US10272064 Expires Apr 3, 2034
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA209988 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.